AstraZeneca said Wednesday that a primary analysis of its Stage 3 trial information confirmed its coronavirus vaccine’s “security” with a 76?fectiveness rate versus symptomatic COVID.
Flashback: The business reported on Monday that a U.S. trial discovered its vaccine 79?ficient, however faced reaction after NIAID stated Tuesday it may have included info that supplied an “ incomplete view of the efficacy data” in its U.S. outcomes.
Our idea bubble, by means of Axios’ Caitlin Owens: A 3 percentage point difference in efficacy isn’t much, however the general public relations damage to the vaccine brought on by the last couple of days may be tough to undo.
By the numbers: Upgraded results include information from 190 symptomatic cases, 50 more than the cases studied in the dataset released Monday.
The brand-new analysis also found:
- 100?ficacy versus extreme or important illness and hospitalization.
- 85?ficacy against symptomatic COVID-19 in individuals ages 65 years and up, a jump from a formerly reported 80%.
What to view: The Food and Drug Administration must discuss the data AstraZeneca sends.
The huge image: AstraZeneca already faced controversy after more than a dozen nations suspended use of its vaccine in mid-March due to reports of embolism in some people who had actually gotten the shot.
- A European Union firm later said there is “ no indication” the vaccine triggers blood clots.
No comments:
Post a Comment